p144
Peptideexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00656825)
Timeline
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- p144
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00781053 | Phase 2 | Jul 1, 2008 | Digna Biotech S.L., ISDIN, University of Florence |
| NCT00574613 | Phase 2 | Sep 1, 2007 | Digna Biotech S.L., ISDIN |
| NCT00656825 | Phase 1 | Mar 1, 2007 | Digna Biotech S.L., ISDIN, Universidad Autonoma de Madrid |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Digna Biotech S.L. | For profit | 3 | 0 | 2 | 2007 |
| ISDIN | For profit | 3 | 3 | 2 | 2007 |
| Universidad Autonoma de Madrid | Academic/Hospital | 1 | 0 | 1 | 2007 |
| University of Florence | Academic/Hospital | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1